In this study, we found that EGFR inhibitor erlotinib did not blocked the activation of STAT3, whereas inhibitors of PI3 K/AKT showed great inhibition in HNSCC cells, suggesting that STAT3 activation in these cells is independent of EGFR pathway. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.